Objective: To evaluate the effects of a tissue-selective estrogen complex (TSEC) composed of bazedoxifene/conjugated estrogens (BZA/CE) on menopausal symptoms, metabolic parameters, and overall safety.
Design: Multicenter, double-blind, placebo- and active-controlled phase 3 trial (Selective estrogens, Menopause, And Response to Therapy [SMART]-1).
Setting: Outpatient clinical.
Patient(s): Healthy, postmenopausal women (n = 3,397) age 40 to 75 with an intact uterus.
Intervention(s): Single tablets of BZA (10, 20, or 40 mg), each with CE (0.625 or 0.45 mg); raloxifene 60 mg; or placebo taken daily for 2 years.
Main Outcome Measure(s): Hot flushes, breast pain, vaginal atrophy, metabolic parameters, and adverse events.
Result(s): BZA (20 mg)/CE (0.625 or 0.45 mg) significantly reduced the frequency and severity of hot flushes and improved measures of vaginal atrophy compared with placebo. At week 12, the daily number of hot flushes decreased by 51.7% to 85.7% with all BZA/CE doses vs. 17.1% for placebo. BZA/CE improved lipid parameters and homocysteine levels, did not significantly change carbohydrate metabolism, and had only minor effects on some coagulation parameters. The incidences of breast pain and adverse events were similar between BZA/CE and placebo.
Conclusion: The TSEC composed of BZA (20 mg)/CE (0.625 or 0.45 mg) is an effective and safe treatment for menopausal symptoms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.fertnstert.2009.03.113 | DOI Listing |
Menopause
January 2025
National Institute of Health, Cheongju, Republic of Korea.
Objectives: We examined the health-related quality of life (HRQoL) during menopause transition (MT) among middle-aged Korean women.
Methods: This cross-sectional study comprised 2,290 middle-aged women who completed web-based questionnaires between 2020 and 2022. Based on self-reported menstrual cycle patterns, menopause status was classified as premenopausal, early or late transition, or postmenopausal.
Menopause
January 2025
Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Objective: Although dysregulated inflammation has been postulated as a biological mechanism associated with post-acute sequelae of severe acute respiratory coronavirus 2 (SARS-CoV-2) infection (PASC) and shown to be a correlate and an outcome of PASC, it is unclear whether inflammatory markers can prospectively predict PASC risk. We examined the association of leukocyte count and high-sensitivity C-reactive protein (hsCRP) concentrations, measured ~25 years prior to the coronavirus disease 2019 (COVID-19) pandemic, with PASC, PASC severity, and PASC-associated cognitive outcomes at follow-up among postmenopausal women.
Methods: Using biomarker data from blood specimens collected during pre-pandemic enrollment (1993-1998) and data on 1,237 Women's Health Initiative participants who completed a COVID-19 survey between June 2021 and February 2022, we constructed multivariable regression models that controlled for pertinent characteristics.
J Dent Sci
January 2025
Department of Periodontology, School and Hospital of Stomatology, Cheeloo College of Medicine, Shandong University & Shandong Key Laboratory of Oral Tissue Regeneration & Shandong Engineering Research Center of Dental Materials and Oral Tissue Regeneration & Shandong Provincial Clinical Research Center for Oral Diseases, Jinan, China.
Background/purpose: Progesterone (PG) is sex steroid hormone that commonly used to control menopausal symptoms, but its exact role in periodontitis remains unclear. This study aimed to investigate the effects of PG on periodontitis in perimenopausal women and in an experimental rat model.
Materials And Methods: Total 412 perimenopausal women with periodontitis and a history of PG deficiency-induced uterine dysfunctional bleeding were enrolled, among which 209 women had been treated with PG.
J Appl Res Intellect Disabil
January 2025
School of Nursing and Midwifery, Trinity College Dublin, Dublin, Ireland.
Background: Negative mental health implications of menopause found in the general population, combined with high rates of mental health conditions found in women with intellectual disabilities, provide rationale to examine the existing literature to determine the impact of menopause on women with intellectual disabilities.
Methods: The review was conducted using scoping review methodology by Arksey and O'Malley. A systematic search was conducted across multiple databases.
Ann Hematol
January 2025
Department of Obstetrics and Gynecology, The Helen Schneider Hospital for Women, Rabin Medical Center, Petach-Tikva, Israel.
Chronic Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT), affecting the female genital tract in 25-66% of the patients. This condition, referred to as Genital GVHD is an underdiagnosed gynecologic comorbidity, that can significantly impair quality of life. We aimed to describe the prevalence and management of genital GVHD following HSCT.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!